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Abstract: IMPORTANCE: The optimal anticoagulant for patients with non-ST-segment elevation acute
coronary syndromes (NSTE-ACS) managed with an invasive strategy remains controversial. OBJEC-
TIVE: To compare the clinical efficacy and safety of otamixaban, a novel intravenous direct factor Xa
inhibitor, with that of unfractionated heparin plus downstream eptifibatide in patients with NSTE-ACS
undergoing a planned early invasive strategy. DESIGN, SETTING, AND PARTICIPANTS: Random-
ized, double-blind, active-controlled superiority trial that enrolled 13,229 patients with NSTE-ACS and
a planned early invasive strategy, at 568 active sites in 55 countries and conducted between April 2010
and February 2013. A planned interim analysis was conducted for otamixaban dose selection. INTER-
VENTIONS: Eligible participants were randomized to otamixaban (bolus and infusion, at 1 of 2 doses) or
unfractionated heparin plus, at the time of percutaneous coronary intervention, eptifibatide. The otamix-
aban dose selected at interim analysis was an intravenous bolus of 0.080 mg/kg followed by an infusion of
0.140 mg/kg per hour. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was the
composite of all-cause death or new myocardial infarction through day 7. RESULTS: Rates of the pri-
mary efficacy outcome were 5.5% (279 of 5105 patients) randomized to receive otamixaban and 5.7% (310
of 5466 patients) randomized to receive unfractionated heparin plus eptifibatide (adjusted relative risk,
0.99 [95% CI, 0.85-1.16]; P = .93). There were no differences for the secondary end points, including pro-
cedural thrombotic complications. The primary safety outcome of Thrombosis in Myocardial Infarction
major or minor bleeding through day 7 was increased by otamixaban (3.1% vs 1.5%; relative risk, 2.13
[95% CI, 1.63-2.78]; P < .001). Results were consistent across prespecified subgroups. CONCLUSIONS
AND RELEVANCE: Otamixaban did not reduce the rate of ischemic events relative to unfractionated
heparin plus eptifibatide but did increase bleeding. These findings do not support the use of otamixa-
ban for patients with NSTE-ACS undergoing planned early percutaneous coronary intervention. TRIAL
REGISTRATION: clinicaltrials.gov Identifier: NCT01076764.
DOI: https://doi.org/10.1001/jama.2013.277165





Steg, Philippe Gabriel; Mehta, Shamir R; Pollack, Charles V; et al (2013). Anticoagulation with otamix-
aban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized
clinical trial. JAMA : the Journal of the American Medical Association, 310(11):1145-1155.
DOI: https://doi.org/10.1001/jama.2013.277165
AnticoagulationWith Otamixaban and Ischemic Events
in Non–ST-Segment Elevation Acute Coronary Syndromes
The TAO Randomized Clinical Trial
Philippe Gabriel Steg, MD; Shamir R. Mehta, MD, MSc; Charles V. Pollack Jr, MD, MA; Christoph Bode, MD; Marc Cohen, MD;William J. French, MD;
James Hoekstra, MD; Sunil V. Rao, MD;Witold Ruzyllo, MD; JuanM. Ruiz-Nodar, MD, PhD; Manel Sabaté, MD; Petr Widimsky, MD; Robert Gabor Kiss, MD;
Jose Luis Navarro Estrada, MD; Hanoch Hod, MD; Prafulla Kerkar, MD; Sema Guneri, MD; Murat Sezer, MD; Mikhail Ruda, MD; José Carlos Nicolau, MD;
Claudio Cavallini, MD; Iftikhar Ebrahim, MD; Ivo Petrov, MD; Jae-Hyung Kim, MD; Myung-Ho Jeong, MD; Gabriel Arturo Ramos Lopez, MD;
Peep Laanmets, MD; Frantisek Kovar, MD; Christophe Gaudin, MD; Karen C. Fanouillere, MSc; Pascal Minini, PhD; Elaine B. Hoffman, PhD;
Angele Moryusef, MD; Stephen D.Wiviott, MD; Marc S. Sabatine, MD, MPH; for the TAO Investigators
IMPORTANCE The optimal anticoagulant for patients with non–ST-segment elevation acute
coronary syndromes (NSTE-ACS) managed with an invasive strategy remains controversial.
OBJECTIVE To compare the clinical efficacy and safety of otamixaban, a novel intravenous
direct factor Xa inhibitor, with that of unfractionated heparin plus downstream eptifibatide in
patients with NSTE-ACS undergoing a planned early invasive strategy.
DESIGN, SETTING, AND PARTICIPANTS Randomized, double-blind, active-controlled
superiority trial that enrolled 13 229 patients with NSTE-ACS and a planned early invasive
strategy, at 568 active sites in 55 countries and conducted between April 2010 and February
2013. A planned interim analysis was conducted for otamixaban dose selection.
INTERVENTIONS Eligible participants were randomized to otamixaban (bolus and infusion, at
1 of 2 doses) or unfractionated heparin plus, at the time of percutaneous coronary
intervention, eptifibatide. The otamixaban dose selected at interim analysis was an
intravenous bolus of 0.080mg/kg followed by an infusion of 0.140mg/kg per hour.
MAIN OUTCOMES ANDMEASURES The primary efficacy outcomewas the composite of
all-cause death or newmyocardial infarction through day 7.
RESULTS Rates of the primary efficacy outcomewere 5.5% (279 of 5105 patients)
randomized to receive otamixaban and 5.7% (310 of 5466 patients) randomized to receive
unfractionated heparin plus eptifibatide (adjusted relative risk, 0.99 [95% CI, 0.85-1.16];
P = .93). There were no differences for the secondary end points, including procedural
thrombotic complications. The primary safety outcome of Thrombosis in Myocardial
Infarctionmajor or minor bleeding through day 7 was increased by otamixaban (3.1% vs 1.5%;
relative risk, 2.13 [95% CI, 1.63-2.78]; P < .001). Results were consistent across prespecified
subgroups.
CONCLUSIONS AND RELEVANCE Otamixaban did not reduce the rate of ischemic events
relative to unfractionated heparin plus eptifibatide but did increase bleeding. These findings
do not support the use of otamixaban for patients with NSTE-ACS undergoing planned early
percutaneous coronary intervention.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01076764
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M
ajor progress has beenmade in the management of
non–ST-segment elevation acute coronary syn-
dromes (NSTE-ACS)becauseof theavailabilityofpo-
tent combinationsoforal antiplatelet agents and injectable an-
ticoagulants and the increasing use of an invasive strategy.1-5
Nevertheless, the risk of adverse outcomes remains
substantial,6 and there is no consensus on a single optimal in-
jectable anticoagulant that can be used across the continuum
of care from the emergency setting through revasculariza-
tion (when applicable). Unfractionated heparin (UFH), par-
ticularly when combined with a glycoprotein IIb/IIIa recep-
tor inhibitor at the timeofpercutaneouscoronary intervention
(PCI),7 remains an effective and widely used therapy, and its
use is supported by US and European guidelines.1,2 Unfrac-
tionated heparin, however, has limitations, including a nar-
row therapeutic window, a somewhat unpredictable antico-
agulant response, and activation of the platelet factor 4
receptor.8 The addition of glycoprotein IIb/IIIa receptor in-
hibitor toUFHat the timeof PCI enhances the efficacy ofUFH
for the treatmentofACS,1,2 although it increases bleeding risk.
The synthetic intravenous direct factor Xa inhibitor, ota-
mixaban, inhibits thrombin generation in a dose-dependent
manner,with a rapidonset andoffset of action, linear kinetics,
and limited renal elimination.9-11 The phase 2, dose-ranging






(SEPIA-ACS1 TIMI 42) trial
involving patients with
NSTE-ACSandaplannedinvasivestrategy,eventhoughnotpow-
ered for efficacy, showed a reduction in the combined out-
comeofdeathormyocardial infarction inpatients treatedwith
otamixaban comparedwithUFHplus eptifibatide and showed
similarbleedingrateswithotamixabanatmidrangedoses.12Pre-
vious studieswith factorXaantagonists inACShave identified
ariskofproceduralthromboticcomplicationsthatmandatecare-
ful titration of these drugs or additional antithrombotic agents
at the time of PCI,13 but thiswas not seen atmidrange doses of
otamixaban. Thus, given its rapid onset and offset, intrave-
nous administration, and predictable anticoagulant response
thatdoesnot requiremonitoring,otamixabanwasattractiveas
a single anticoagulant to be used across the continuumof care
for NSTE-ACS, from emergency care through intervention.
The Treatment of Acute Coronary Syndromes with Ota-
mixaban (TAO) trialwasdesignedas a superiority trial to com-
pare the clinical efficacy and safety of otamixaban with that
of UFH plus downstream eptifibatide in patients with NSTE-
ACS with a planned invasive strategy.
Methods
Study Patients
The design of the TAO trial has been published.14 In brief,
eligible patients were those with NSTE-ACS scheduled to
undergo an early invasive strategy (angiography and PCI, if
indicated, to be performed within 36 hours of randomiza-
tion and at the latest on day 3; eTable 1 in the Supplement).
All patients provided written informed consent. In every
participating country, the study was approved by ethics
committees in accordance with local guidelines. The main
exclusion criteria were revascularization procedure already
performed for the qualifying event; acute ST–segment
elevation myocardial infarction; receipt of a therapeutic
dose of injectable anticoagulant for more than 24 hours
before randomization; or treatment with abciximab. If
received in the 24 hours before randomization, treatment
with UFH or bivalirudin must have been discontinued at
least 90 minutes but no longer than 150 minutes before
starting otamixaban and the last dose of low-molecular-
weight heparin or fondaparinux must have been received at
least 8 hours before starting otamixaban.
Study Treatments
The studyused a double-blind design,with 2 stages.14During
the first stage, until a planned interim analysis, patientswere
randomized using a centralized interactive voice–web re-
sponse system, stratified by center, to the UFH-plus-
eptifibatide group or to 1 of 2 otamixaban dosing groups (in-
travenous bolus of 0.080 mg/kg followed by an infusion of
either 0.100mg/kgper hour or 0.140mg/kgper hour) in a 1:1:1
ratio (eFigure 1 in the Supplement). The infusions of otamixa-
ban or placebo andUFHor placebowere initiated anddiscon-
tinuedsimultaneously.Theplanned interimanalysis, tobeper-
formedafterat least 1969patientshadbeenrandomized ineach
group and had completed a 7-day follow-up (approximately
35%fractional information), allowed thedatamonitoringcom-
mittee tochoose (usingapredefinedalgorithmandwhilemain-
taining the blind for patients, investigators, and sponsor) the
optimal otamixaban-dose group (in this case the higher-dose
group) to continue until study end. Thus, in the second stage,
patientswere randomized in a 1:1 ratio either to theUFH-plus-
eptifibatidegroupor to theotamixabangroup (intravenousbo-
lus of 0.080 mg/kg followed by a 0.140-mg/kg per hour infu-
sion). Investigators andpatientswereblinded for thedrugand
the dose.
In the UFH-plus-eptifibatide group, throughout both
study stages, patients received UFH (60-IU/kg intravenous
bolus [maximum, 4000 IU] followed by an infusion of 12
IU/kg per hour [maximum, 1000 IU/h] to maintain an acti-
vated partial thromboplastin time at 1.5-2.0 times the con-
trol group) as soon as possible after randomization and con-
tinued until the end of PCI. At the time of PCI, additional
UFH boluses could be administered if the activated clotting
time was not in the 200- to 250-seconds range. For the
investigators to remain blinded, all activated partial throm-
boplastin time–activated clotting times completed to adjust
UFH or placebo were performed using an encrypted device
(Hemochron Signature Elite machine, International Techni-
dyne Corp).
Blinded treatment with eptifibatide was initiated at the
start of PCI, with a 180-μg/kg bolus immediately before PCI,
followedbyacontinuous infusionof 2.0μg/kgperminute, and






Research Original Investigation Otamixaban for Non–ST-Segment Elevation ACS
1146 JAMA September 18, 2013 Volume 310, Number 11 jama.com
Downloaded From: https://jamanetwork.com/ by a UZH Hauptbibliothek / Zentralbibliothek Zuerich User  on 05/18/2021
a second 180-μg/kg bolus 10 minutes later. For patients with
a creatinine clearance lower than50mL/min, the infusion rate
wasreducedto1μg/kgperminute.The infusionwas tobegiven
for 18 to 24 hours after PCI or until hospital discharge, which-
ever came first, with an option for blinded bailout eptifiba-
tide (for those randomizedtootamixaban)orplacebo (for those
originally randomizedtoUFHpluseptifibatide) tobegivenonly
when deemed necessary by the investigator (who remained
blinded to all studydrugs). If angiographydid not lead to PCI,
eptifibatide or placebo was not administered and the dura-
tion of anticoagulation with UFH and placebo and otamixa-
ban and placebo was left to the investigator’s discretion, but
could not exceed 4 days or to hospital discharge, whichever
came first.
In addition to the blinded study medication, all ran-
domized patients were to receive both aspirin and an oral
adenosine diphosphate receptor antagonist (eg, clopidogrel,
prasugrel, ticagrelor) in accordance with local label or
guidelines.
Outcomes
Theprimary efficacy outcomewas the composite of all-cause
deathornewmyocardial infarction fromrandomization today
7. Secondary efficacy outcome measures included the pri-
mary outcomeup today 30, the composite of all-cause death,
new myocardial infarction, or any stroke from randomiza-
tion today 7; rehospitalization or prolongation of hospitaliza-
tion due to a new episode of myocardial ischemia ormyocar-
dial infarction from randomization to day 30; all-cause death
from randomization to day 30; and periprocedural and post-
procedural thrombotic complicationsduring the indexPCI (in-
cludingpostprocedural stent thromboses, categorizedaccord-
ing to the Academic Research Consortium classification15).
Myocardial infarctionswere categorizedaccording to the 2007
universal definition.16 Key efficacy and safety outcomes, in-
cluding all procedural complications, were adjudicated by a
clinical events committee (TIMI Study Group, eAppendix in
the Supplement), unaware of treatment assignments, and, in
the case of procedural complications, with review of the an-
giograms.
Theprimary safetyoutcomewas the composite ofThrom-
bosis in Myocardial Infarction (TIMI) major or minor bleed-
ing (coronary artery bypass graft [CABG]–related and non–
CABG-relatedsurgery),measured fromrandomization through
day 7. Other safety outcome measures included CABG-
related and non–CABG-related bleedings according to the
GlobalUtilizationofStreptokinaseand t-PA forOccludedCoro-
nary Arteries (GUSTO), Bleeding Academic Research Consor-
tium (BARC),17 and Clopidogrel andAspirin Optimal Dose Us-
age to Reduce Recurrent Events—Seventh Organization to
AssessStrategies in IschemicSymptoms (CURRENT-OASIS7)18
classifications.
Statistical Analysis
Assuming an event rate of the composite of all-cause death or
new myocardial infarction through day 7 in the UFH-plus-
eptifibatidegroupof5.0%,a relative risk (RR) reductionof25%,
a binomial 1-sided (α = .025) superiority test for the compari-
son of 2 proportions, and a 2-stage adaptive design with 1 in-
terim analysis at 35% fractional information, simulations
showed that 13 220 patients (5625 per group for the 2-stage,
2-group study)would yield 88%power for demonstrating the
superiority of otamixaban.
At the interim analysis planned after at least 1969
patients had been randomized and reached day 7 follow-up
in each group,14 the otamixaban dose for stage 2 of the trial
was selected as described in eFigure 1 in the Supplement.
At that time, the rates of the primary efficacy outcome in
the higher-dose otamixaban group was 4.7% (the one
selected to go forward) and was 5.6% in the UFH-plus-
eptifibatide group (adjusted RR, 0.848; 95% CI, 0.662-1.087)
but the lower-dose group fulfilled the prespecified criteria
for futility with a RR of more than 1 (primary efficacy out-
come, 6.3%; RR, 1.130; 95% CI, 0.906-1.408) and was discon-
tinued.
All efficacy analyses and bleeding analyses were per-
formed on the intention-to-treat population, except for
thrombotic procedural complications, which were analyzed
on the randomized PCI population (ie, all randomized
patients who underwent an index PCI). The primary effi-
cacy outcome comparison used the Fisher exact test and a
closed testing procedure for ensuring a global 2-sided α level
of .05.14 Secondary outcomes were to be examined in a hier-
archical testing procedure if the primary outcome reached
statistical significance. Events occurring among patients
who received the discontinued otamixaban dose were not
considered in primary outcome analyses, which pertained
only to participants randomized to the higher dose of ota-
mixaban vs UFH plus eptifibatide, not to the low-dose ota-
mixaban group. There was no prespecified testing for safety
variables. For efficacy and safety outcomes, the 6 patients
without an event and who were not followed up to day 7
were considered event free at day 7 (for both efficacy and
safety events), unless otherwise specified. Continuous vari-
ables are reported as medians (interquartile ranges [IQRs]).
Categorical variables are reported as frequencies and per-
centages. Analyses were performed using SAS version 9.2
(SAS Institute Inc).
Results
Patient Characteristics and Treatments
Overall, 13 229 patients were randomized into the trial from
568 active sites in 55 countries between April 2010 and Feb-
ruary 2013 (Figure 1). At the prespecified interim analysis,
the data monitoring committee terminated enrollment of
patients to the 0.100-mg/kg per hour otamixaban group
because of futility (efficacy hazard ratio [HR] >1.0 vs UFH
plus eptifibatide) and thus selected the 0.140-mg/kg per
hour otamixaban group to continue enrollment until the
end of the trial.
The baseline characteristics of the 13 229 randomized
patients were well matched between groups and typical of
an ACS trial population. Overall, 11 646 patients (88.0%) of
the population had elevated biomarkers and 5404 (40.8%)
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had electrocardiographic changes; 4994 patients (37.9%)
had ST-segment depression of at least 1 mm, 769 (5.8%) had
transient ST elevation, and 281 (2.1%) had left bundle-
branch block. Approximately 40% of the patients had a
GRACE (Global Registry of Acute Coronary Events) risk
score higher than 133 points.
Treatments given during the index hospitalization are
summarized in Table 1, which compares those included in
the primary efficacy analysis. Almost all patients received
aspirin and an oral adenosine diphosphate receptor antago-
nist, with a majority taking clopidogrel, with a 600-mg or
higher loading dose in 28.2% (n = 3736). The adenosine
diphosphate antagonist was almost always (97.3%) adminis-
tered prior to PCI, at a median interval of 16:00 hours (IQR,
6:37-23:15 hours) before PCI. A total of 8320 patients (62.9%)
had received an injectable nonstudy drug anticoagulant in
the 24 hours before randomization, mostly low-molecular-
weight heparin or UFH. Angiography was performed in
13 125 patients (99.2%) and led to PCI in 8656 patients
(65.4%) and to CABG surgery in 682 patients (5.2%). Radial
access was used in more than half of the patients in both
groups. The median duration of study anticoagulant admin-
istration was 4:06 hours (IQR, 3:12-9:44 hours) in the ota-
mixaban group and 4:12 hours (IQR, 3:14-11:50 hours) in the
UFH-plus-eptifibatide group. Study anticoagulant was pre-
maturely discontinued in 413 patients (8.1%) in the otamixa-
ban group and in 306 (5.6%) of the UFH plus eptifibatide
group (P < .001).
Efficacy
Follow-up to day 7 was available for 13 223 (99.95%) of the
patients. The primary outcome of death or myocardial
infarction through day 7 occurred in 5.5% of the patients
treated with otamixaban 0.140 mg/kg per hour vs 5.7% of
the patients treated with UFH plus eptifibatide (RR, 0.99
[95% CI, 0.85-1.16]; P = .93; Table 2 and Figure 2). Otamixa-
ban did not significantly reduce the risk of any of the
components of the primary outcomes, either death or myo-
cardial infarction (of which the vast majority were periproce-
dural), or of any of the secondary efficacy outcomes
(Table 2). The rate of thrombotic procedural complications
was 4.0% in patients treated with otamixaban vs 4.6% in
patients treated with UFH plus eptifibatide (RR, 0.88 [95%
CI, 0.70-1.10]; Table 2; and eTable 2 in the Supplement); in
particular, the rates of stent thrombosis were 1.3% vs 1.6%
(RR, 0.81; 95% CI, 0.55-1.20) and the rates of catheter or
guidewire thrombus were less than 0.1% vs 0.3% (RR, 0.12;
95% CI, 0.02-0.94). Analysis of the primary outcome by 30
days confirmed the absence of a reduction with otamixaban
(RR, 1.02 [95% CI, 0.89-1.17]; P >.99).
In the lower-dose otamixabangroup, discontinuedby the
data monitoring committee for futility based on the interim
analysis, the rate of the primary outcome at day 7 was 6.3%
(adjusted RR, 1.11; 95% CI, 0.92-1.33; eFigure 2 in the Supple-
ment). The efficacy and safety outcomes with otamixaban
0.100 mg/kg per hour vs UFH plus eptifibatide are shown in
eTable 3 in the Supplement.
Figure 1. Patient Flow Chart
2657 Randomized to receive
otamixaban IV bolus of 0.080 mg/
kg followed by 0.100 mg/kg per h
2639 Received intervention as
randomized
18 Did not receive intervention
as randomized
5106 Randomized to receive
otamixaban IV bolus of 0.080 mg/
kg followed by 0.140 mg/kg per h
5065 Received intervention as
randomized
41 Did not receive intervention
as randomized
5466 Randomized to receive
unfractionated heparin +
eptifibatide
5424 Received intervention as
randomized
42 Did not receive intervention
as randomized





2657 Included in the primary analyses
2639 Included in adverse event analysis
18 Excluded (not treated)
5106 Included in the primary analyses
5065 Included in adverse event analysis
41 Excluded (not treated)
5466 Included in the primary analyses
5424 Included in adverse event analysis
42 Excluded (not treated)
1 Lost to follow-up
190 Discontinued intervention
25 Had adverse event
6 Had new episode of ischemia/
infarction
2 Had stroke




3 Lost to follow-up
413 Discontinued intervention
33 Had adverse event
7 Had new episode of
ischemia/infarction
3 Had stroke




2 Lost to follow-up
306 Discontinued intervention
42 Had adverse event
13 Had new episode of ischemia/
infarction
4 Had stroke




The top reasons for screening failure
include 75 patients living in countries
in which labeling for eptifibatide is
not approved for this use, 50 patients
who received anticoagulatant
treatment or abciximab, 12 patients
who would not likely be available for
follow-up at 180 days, 10 patients
who were unable to discontinue their
current anticoagulation in order to
transition to investigational products,
and 10 patients who could not be
treated by aspirin and clopidogrel or
another antiplatelet agent according
to their country’s local labeling.
PCI indicates percutaneous coronary
intervention.
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Table 1. Baseline Characteristics of the Patients, Procedure Characteristics, and Treatments in the Intention-to-Treat Population According to
Treatment Group
Factor
No. (%) of Patientsa
Otamixaban (0.080-mg/kg Bolus
and 0.140-mg/kg per Hour Infusion)
(n = 5106)
Unfractionated Heparin + Eptifibatide
(n = 5466)
Age, median (range), y 62 (25-94) 62 (20-92)
Women 1545 (30.3) 1641 (30.0)
Whiteb 4454 (87.2) 4739 (86.7)
Body weight, median (IQR), kg 80 (37-168) 79 (37-198)
BMI, median (range) 27.7 (15.2-65.8) 27.6 (15.1-69.3)
Region
North America (US and Canada) 663 (13.0) 717 (13.1)
Western Europe 1014 (19.9) 1042 (19.1)
Eastern Europe 1713 (33.5) 1828 (33.4)
Asia 428 (8.4) 490 (9.0)
Otherc 1288 (25.2) 1389 (25.4)
Baseline creatinine clearance, median (IQR), mL/mind 90 (68-115) 89 (68-114)
Medical history
Diabetes mellitus 1427 (27.9) 1581 (28.9)
Hypertension 3624 (71.0) 3907 (71.5)
Current smoker 1719 (33.7) 1817 (33.3)
Stroke or TIA 267 (5.2) 282 (5.2)
Myocardial infarction 965 (18.9) 1055 (19.3)
Inclusion criteria
Biomarker elevatione 4523 (90.2) 4834 (88.4)
ECG changesf 2042 (40.0) 2232 (40.8)
Time since onset of last episode and randomization, median (IQR), h 15 (9-20) 15 (8-20)
TIMI risk score category at baselineg
0-2 1596 (31.3) 1686 (30.8)
3-4 2502 (49.0) 2629 (48.1)
5-7 1008 (19.7) 1151 (21.1)
GRACE risk score category at baselineh
<96 690 (14.5) 714 (14.0)
96-112 872 (18.4) 942 (18.5)
113-133 1353 (28.5) 1426 (27.9)
>133 1831 (38.6) 2023 (39.6)
Anticoagulant use in the 24 h before randomization
Unfractionated heparin 1538 (30.1) 1668 (30.5)
LMWH 1682 (32.9) 1786 (32.7)
Fondaparinux 185 (3.6) 193 (3.5)
Bivalirudin 2 (<0.1) 1 (<0.1)
Antiplatelet therapy taken within 24 h before randomization (and/or long-term)
Aspirin 4932 (96.6) 5282 (96.6)
Oral ADP receptor antagonist 4430 (86.8) 4700 (86.0)
Clopidogrel 4186 (82.0) 4467 (81.7)
Prasugrel 126 (2.5) 115 (2.1)
Ticagrelor 151 (3.0) 168 (3.1)
Antiplatelet therapy received between randomization and discharge
Aspirin 4949 (96.9) 5307 (97.1)
Oral ADP receptor antagonist 4646 (91.0) 4971 (90.9)
Clopidogrel 4294 (84.1) 4602 (84.2)
Prasugrel 251 (4.9) 274 (5.0)
Ticagrelor 205 (4.0) 218 (4.0)
(continued)
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Subgroups
Theeffect ofotamixabanon theprimaryefficacyoutcomewas
examined across prespecified subgroups anddid not differ as
a function of baseline characteristics, medical history, prior
treatment with antithrombotic agents, disease characteris-
tics, or patientmanagement (Figure 3). The outcome also did
not differ as a function of baseline risk assessed by the TIMI
orGRACErisk scores (nonprespecified subgroups)or as a func-
tion of duration of infusion of study drug anticoagulant (sub-
group defined after randomization; Figure 3 and eFigure 3A
in the Supplement). There was a nonsignificant sex-by-
treatment interaction (P = .053).
Safety
Patients in the otamixaban group had an increased rate of
the primary safety outcome of TIMI major or minor bleeding
at day 7 compared with patients in the combination of UFH-
plus-eptifibatide group (3.1% vs 1.5%; RR, 2.13 [95% CI, 1.63-
2.78]; P < .001; Table 2). Otamixaban consistently increased
all types of bleeding events, regardless of the severity or
bleeding classification scheme used (Table 2; and eTable 4
in the Supplement), and without interaction across patient
subsets, including demographics, previous treatment, risk
scores, biomarkers or management (eFigure 3B and eFigure
4 in the Supplement). Study anticoagulant was discontin-
ued because of bleeding in 242 patients (4.7%) in the ota-
mixaban group and in 95 patients (1.7%) in the UFH-plus-
eptifibatide group (P < .001). Except for bleeding, there
were no differences in the rate of adverse events or serious
adverse events or liver-function abnormalities (eTable 5 in
the Supplement). The lower dose of otamixaban (before this
dose group was discontinued at the interim analysis)
increased the rate of the primary safety outcome (TIMI
major or minor bleeding up to day 7) compared with UFH
plus eptifibatide (RR, 1.57; 95% CI, 1.13-2.18).
Discussion
Compared with UFH and eptifibatide, otamixaban was not
superior in reducing the risk of ischemic outcomes in
patients with NSTE-ACS whose conditions were managed
with an invasive strategy. Meanwhile, the risk of major or
minor bleeding was approximately doubled with otamixa-
ban. These results were consistent across patient sub-
groups. A lower dose of otamixaban did not achieve better
results.
The SEPIA-ACS1 TIMI 42 dose-ranging trial had sug-
gested a clinical benefit of otamixaban in NSTE-ACS, in a
population similar to that enrolled in TAO.12 In a post hoc
Table 1. Baseline Characteristics of the Patients, Procedure Characteristics, and Treatments in the Intention-to-Treat Population According to
Treatment Group (continued)
Factor
No. (%) of Patientsa
Otamixaban (0.080-mg/kg Bolus
and 0.140-mg/kg per Hour Infusion)
(n = 5106)
Unfractionated Heparin + Eptifibatide
(n = 5466)
Treatment received between randomization and discharge
Statin 4692 (91.9) 5050 (92.4)
ACE inhibitor or angiotensin receptor blocker 3915 (76.7) 4240 (77.6)
β-Blocker 4214 (82.5) 4488 (82.1)
Management during the index admission
Coronary angiography 5054 (99.0) 5432 (99.4)
PCI 3328 (65.2) 3554 (65.0)
CABG surgery 251 (4.9) 295 (5.4)
Neither PCI nor CABG 1475 (28.9) 1583 (29.0)
Access route for angiography
Femoral 2305 (45.6) 2592 (47.7)
Radial or other 2749 (54.4) 2838 (52.3)
Time between randomization and angiography, median (IQR), min 239 (185-370) 241 (185-396)
Duration of study anticoagulant, median (IQR), min 246 (192-584) 252 (194-710)
Abbreviations: ACE, angiotensin-converting enzyme; ADP, adenosine
diphosphate; BMI, bodymass index, calculated as weight in kilograms divided
by height in meters squared; CABG, coronary artery bypass graft; ECG,
electrocardiogram; GRACE, Global Registry of Acute Coronary Events; IQR,
interquartile range; LMWH, low-molecular-weight heparin; PCI, percutaneous
coronary intervention; TIA, transient ischemic attack; TIMI, Thrombolysis in
Myocardial Infarction.
a Population sizes vary according to characteristics studied.
bSelf-reported from a category list.
c Argentina, Australia, Brazil, Chile, Colombia, Egypt, Israel, Jordan, Lebanon,
Mexico, New Zealand, Panama, Peru, South Africa, Tunisia, Turkey.
dComputed using the Cockroft and Gault formula.
e Elevation of cardiac biomarkers within 24 hours of randomization, defined as
elevated troponin T, troponin I, or creatine kinase MB higher than the upper
limit of normal.
f New ST-segment depression 0.1 mV or higher (1 mm), or transient (<30min)
ST-segment elevation 0.1 mV or higher (1 mm) in at least 2 contiguous leads
on the ECG.
g TIMI score of 0 to 2 indicates low risk of death or ischemic events; 3 to 4,
intermediate risk; and 5 or higher, high risk.
hGRACE score less than 113 indicates low risk for hospital death; 113 to 139,
intermediate risk; and 140 or higher, high risk.
Research Original Investigation Otamixaban for Non–ST-Segment Elevation ACS
1150 JAMA September 18, 2013 Volume 310, Number 11 jama.com
Downloaded From: https://jamanetwork.com/ by a UZH Hauptbibliothek / Zentralbibliothek Zuerich User  on 05/18/2021
analysis, a 44% to 48% RR reduction in death or myocardial
infarction was seen in the midrange doses compared with
UFH plus eptifibatide, similar to those tested in the TAO
trial. However, even though SEPIA-ACS1 was a large, dose-
ranging trial, with 3241 patients, there were only 17 to 22
deaths or myocardial infarctions in each group; conse-
quently, there were wide confidence intervals around the
point estimates for effect size, which overlap the effect seen
in TAO (eFigure 5 in the Supplement). Moreover, in a dose-
ranging trial, a relatively high event rate in the UFH-plus-
eptifibatide group can falsely inflate the estimated treat-
ment effect across multiple experimental groups, hence the
need for a definitive phase 3 trial such as TAO, with 15-fold
more outcomes per group.
Anotherdifferencebetweenthe2 trials is thedosingofepti-
fibatide: inSEPIA-ACS112asingleboluswasadministeredat ran-
domization,whereas inTAOeptifibatidewasgivenas adouble
bolus but only in patients undergoing PCI, as recommended
inguidelines.1,2Thisdifferencemayhaveaffectedefficacyand
safety, explaining in particular why the excess risk of bleed-
ing with otamixaban appeared greater in TAO than in SEPIA-
ACS1. The rates of deathormyocardial infarctionwere slightly
Table 2. Efficacy and Safety Outcomes at 7 Days and at 30Days After Randomization
Outcome












Efficacy outcomes (intent-to-treat population)
Primary efficacy outcomes: all-cause death
or MI at day 7
279 (5.5) 310 (5.7) 0.99 (0.85-1.16)
Components of primary efficacy outcomes
All-cause death 53 (1.0) 47 (0.9) 1.21 (0.82-1.78)
MI 239 (4.7) 276 (5.0) 0.93 (0.78-1.10)
Type of MI (universal definition16)b
Type 1 20 (0.4) 31 (0.6) 0.69 (0.39-1.21)
Type 2 0 2 (<0.1) Not estimable
Type 3 0 0 Not estimable
Type 4a 180 (3.5) 206 (3.8) 0.94 (0.77-1.14)
Type 4b 8 (0.2) 12 (0.2) 0.71 (0.29-1.74)
Type 5 35 (0.7) 28 (0.5) 1.34 (0.82-2.20)
Secondary outcomes
All-cause death, MI, or stroke at day 7 298 (5.8) 324 (5.9) 0.98 (0.85-1.15)
Procedural thrombotic complications during
index PCI
(n = 3328) (n = 3554)
Any 134 (4.0) 163 (4.6) 0.88 (0.70-1.10)
Stent thrombosis (ARC15) 44 (1.3) 58 (1.6) 0.81 (0.55-1.20)
Stroke at day 7 20 (0.4) 16 (0.3) 1.34 (0.69-2.58)
Efficacy outcomes (intent-to-treat population)
at day 30
All-cause death or MI 354 (6.9) 383 (7.0) 1.02 (0.89-1.17)
Rehospitalization or prolonged hospitaliza-
tion due to new ischemia/MI
81 (1.6) 96 (1.8) 0.90 (0.67-1.21)
All-cause death 90 (1.8) 85 (1.6) 1.17 (0.87-1.58)
MI 288 (5.6) 325 (5.9) 0.95 (0.81-1.11)
Safety outcomesb
Primary safety outcome (TIMI major
or minor bleeding at day 7)
159 (3.1) 80 (1.5) 2.13 (1.63-2.78)
TIMI major 89 (1.7) 41 (0.8) 2.32 (1.61-3.36)
Non–CABG-related major 46 (0.9) 21 (0.4) 2.35 (1.40-3.92)
CABG-related major 43 (0.8) 20 (0.4) 2.30 (1.36-3.91)
TIMI minor 71 (1.4) 40 (0.7) 1.90 (1.29-2.79)
Any clinically overt bleed 607 (11.9) 306 (5.6) 2.12 (1.86-2.42)
TIMI requiring medical attention 359 (7.0) 169 (3.1) 2.27 (1.90-2.72)
TIMI minimal 136 (2.7) 55 (1.0) 2.65 (1.94-3.61)
Intracranial bleeding 5 (<0.1) 1 (<0.1) 5.35 (0.63-45.80)
Abbreviations: ARC, Academic
Research Consortium; CABG,
coronary artery bypass graft; CI,






a vs Unfractionated heparin and
eptifibatide.
bA patient can be counted in several
categories: type 1, spontaneous MI;
type 2, MI secondary to ischemia;
type 3, sudden unexpected cardiac
death; type 4a, MI associated with
PCI; type 4b, MI associated with
stent thrombosis; type 5, MI
associated with CABG surgery.
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higher in TAO than in SEPIA-ACS1, possibly reflecting the in-
creasedsensitivityof troponins. InSEPIA-ACS1,myocardial in-
farctions were evenly distributed between spontaneous and
periprocedural, whereas in TAO approximately three-
quartersof themyocardial infarctionswereperiprocedural.The
abilityofanyanticoagulant (asopposed toantiplatelet therapy)
to affect the proportion of patients exhibiting peri-PCI eleva-
tion in the era of more sensitive cardiac biomarkers of necro-
sis may be more limited.
Procedural thrombotic complications were increased at
lower doses of otamixaban in SEPIA-ACS112 and thus played
an important role in selecting the dose for phase 3. The TAO
study confirmed that with sufficiently high doses of intrave-
nous Xa inhibition, procedural thrombotic complications do
not appear tobean issue. InTAO, the rateof guidewireor cath-
eter thrombosis was lower with otamixaban. This contrasts
with previous experiences with low doses of an Xa inhibitor
with fondaparinux in the OASIS-7 trial19 and may be related
to the relatively high dose of otamixaban used in this trial,
whichwas associatedwith increasedbleeding comparedwith
UFH plus eptifibatide.
Despite the limitations of UFH as an anticoagulant,8 no
single agent has emerged as an unambiguous standard of
care for anticoagulation in NSTE-ACS, and guidelines offer
several options, with UFH, bivalirudin, low-molecular-
weight heparin, or fondaparinux.1,2 Consequently, there is
marked variation in the use of anticoagulants for ACS, with
frequent overlap between multiple anticoagulants, particu-
larly when ACS patients proceed to PCI.20-25 Otamixaban is
theoretically attractive as anticoagulant for NSTE-ACS: it is
an injectable agent with rapid onset and offset, modest
renal elimination, and predictable anticoagulant effect that
obviates the need for monitoring. The TAO results, however,
demonstrate lack of efficacy benefit but marked increases in
bleeding when compared with UFH plus a glycoprotein
IIb/IIIa receptor inhibitor, even with the majority of patients
undergoing transradial PCI.
The lack of difference between otamixaban and UFH plus
eptifibatidewas not related to lack of power. In fact, the global
studypowerbasedon theobservedevent rate in theUFH-plus-
eptifibatide group was 90.3%, higher than the planned 88%
power.14 TAOwas a superiority trial, and although there is the
possibility that otamixabanmight have achieved noninferior-
ity to UFH plus eptifibatide, the consistent increase in bleed-
ing makes use of otamixaban a nonviable clinical option, and
it isunlikelythatahigherotamixabandosewouldhaveachieved
superior efficacy results without intolerable bleeding. Con-
versely, a reduced dose also had increased bleeding compared
withUFHpluseptifibatide,withnumericallyhigher ratesof is-
chemic outcomes thanUFHplus glycoprotein IIb/IIIa receptor
inhibitor. These results suggest a narrow therapeutic window
for acute Xa inhibition and that increasing the intensity of an-
ticoagulation via this mechanismwill not achieve superior ef-
ficacy-safetybalance inACS in themoderneraof intervention,
when patients are receiving combined injectable anticoagula-
tion, dual antiplatelet therapy, and routine early intervention.
Study Limitations
Most patients (62.9%) had received injectable anticoagula-
tion before randomization, and the duration between onset
of the ischemic episode and randomization was more than
12 hours in a majority of patients. Conversely, the duration
of study drug infusion was relatively brief, reflecting the
short interval between presentation and angiography in
contemporary practice and therefore the limited time for
novel agents to bring differential benefit. Both these factors
would tend to attenuate the effect of study treatment on
outcomes. However, exclusion of patients who had received
a prior anticoagulant would have made enrollment
extremely challenging, and delaying angiography to maxi-
mize study drug duration would be impractical and possibly
unethical. Furthermore, these limitations were also present
in SEPIA-ACS1, and, within TAO, the treatment effects did
not appear affected by pretreatment with anticoagulation or
Figure 2. Kaplan-Meier Analyses of the Primary Efficacy Outcome for Otamixaban, 0.140mg/kg per Hour vs
Control
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Dotted line indicates day 7.
Primary efficacy outcomes include
all-cause death or myocardial
infarction at day 7.
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according to duration elapsed between the last ischemic
episode and randomization. In routine clinical practice,
many patients with ACS do not receive glycoprotein IIb/IIIa
receptor inhibitors.20-22 Therefore, otamixaban, compared
with UFH alone, might have achieved superior efficacy;
however, this benefit would likely have been achieved at the
expense of a higher increase in bleeding risk. Almost all
patients in this trial and in SEPIA-ACS 1 were treated with
clopidogrel; the efficacy and safety of potentially lower
doses of otamixaban on a background of stronger adenosine
diphosphate receptor blockade remain unknown. Unfrac-
tionated heparin plus eptifibatide was selected as the con-
trol treatment. Other regimens might have offered a differ-
ent benefit-risk profile,13,19,26,27 but because otamixaban did
not display superior efficacy and did show worse safety, this
point is moot.
Figure 3. Selected Subgroup Analysis of the Primary Efficacy Outcome at Day 7 in the Otamixaban, 0.140











































No. With Primary Outcome/





Overall 0.99 (0.85-1.16)279/5106 310/5466
<65 1.01 (0.81-1.26)148/3019 155/3205
65-<75 0.88 (0.65-1.18)75/1325 92/1428
Men 0.86 (0.71-1.05)175/3561 218/3825
Women 1.20 (0.91-1.58)104/1545 92/1641
≥75 0.97 (0.69-1.37)56/762 63/833
<60 1.14 (0.72-1.80)35/416 33/448
60-<100 0.97 (0.81-1.17)210/3997 234/4342
≥100 0.78 (0.50-1.23)33/687 41/670
Asia 1.10 (0.62-1.94)22/428 23/490
Eastern Europe 1.07 (0.79-1.45)79/1713 79/1828
Western Europe 1.03 (0.71-1.49)52/1014 52/1042
<50 0.94 (0.61-1.47)34/439 39/475
50-80 1.00 (0.76-1.32)94/1510 101/1628
Yes 1.01 (0.75-1.35)82/1427 90/1581
No 0.95 (0.78-1.14)197/3679 220/3885
Yes 0.89 (0.47-1.69)16/267 19/282
No 0.97 (0.82-1.14)263/4837 291/5181
Yes 0.89 (0.69-1.14)106/2059 131/2259
No 1.02 (0.83-1.25)173/3047 179/3207
Yes 1.02 (0.83-1.24)177/3201 186/3420
No 0.88 (0.68-1.14)102/1905 124/2046
With PCI index 0.91 (0.76-1.09)210/3328 246/3554
CABG surgery index 1.42 (0.93-2.16)41/251 34/295
PCI or index CABG
without indexa 
0.87 (0.49-1.53)21/1475 26/1583
Femoral 0.98 (0.78-1.22)137/2381 156/2654
Nonfemoral 0.93 (0.75-1.17)135/2673  150/2776
>80 0.94 (0.76-1.16)147/3115 167/3321
North America 0.79 (0.52-1.21)36/663 49/717
Other 0.91 (0.69-1.19)90/1288 107/1389
<5 0.95 (0.77-1.18)153/3149 169/3321
5-<12 0.65 (0.43-0.98)35/734 55/752
12-<24 1.13 (0.81-1.57)66/807 63/869
1.47 (0.84-2.56)≥24 25/373 22/481
<12 1.08 (0.83-1.42)99/1856 101/2053
≥12 0.90 (0.75-1.10)180/3246 209/3409
The x-axis is on a logarithmic scale.
Primary efficacy outcomes include
all-cause death or myocardial
infarction at day 7. CABG indicates
coronary artery bypass graft; MI,
myocardial infarction; PCI,
percutaneous coronary intervention;
TIA, transient ischemic attack; and
UFH, unfractionated heparin.
aDefined after randomization.
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Conclusion
Otamixaban did not reduce ischemic events compared with
UFH plus eptifibatide but increased bleeding among patients
with NSTE-ACS and a planned invasive strategy. These find-
ings do not support the use of otamixaban for patients with
NSTE-ACS undergoing planned early percutaneous coronary
intervention.
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